← Back to patent-cliff list
CAS 110-85-0
piperazinePiperazineDiethylenediamine1,4-Diazacyclohexane
Codes: PALB-042, OLAP-013, RIBO-012, BREX-006, VORT-004, Rifampicin-001, RANO-004, POSA-037, Urapidil-012
Physicochemical properties & identification
- Appearance
- White to colourless crystals or flakes; strongly hygroscopic, with an amine odour
- Solubility
- Very readily soluble in water and ethanol; a strong base (pKa1 ≈ 5.6 / pKa2 ≈ 9.8)
- Storage
- Seal under nitrogen and protect from moisture; keep away from acids and oxidising agents
Applications
- · Pharmaceutical building block: the core amine source for piperazine-ring CNS drugs such as aripiprazole, brexpiprazole and cariprazine
- · Raw material for the anthelmintic piperazine salts (citrate / phosphate)
- · CO2 capture (activator in MDEA formulations); epoxy curing agent
Application context (from source-drug indications)
Breast cancerPalbociclibEndometrial cancerOlaparibCastration-resistant prostate cancerOlaparibProstate cancerOlaparibPeritoneal cancerOlaparibEpithelial ovarian cancerOlaparibFallopian tube cancerOlaparibBreast cancerRibociclib SuccinateSchizophreniaBrexpiprazoleAlzheimer's diseaseBrexpiprazoleAgitationBrexpiprazoleDepressionBrexpiprazoleDepressive disorderBrexpiprazoleMajor depressive disorderBrexpiprazoleMajor depressive disorderVortioxetine HydrobromidePostoperative painVortioxetine HydrobromideCannabis dependenceVortioxetine HydrobromideAnxietyVortioxetine HydrobromideAnxiety disorderVortioxetine HydrobromideDepressionVortioxetine HydrobromideMycobacterium tuberculosis infectionEthambutol Hydrochloride/Rifampicin/IsoniazidAngina pectorisRanolazineMyocardial infarctionRanolazineAmyotrophic lateral sclerosisRanolazineStable anginaRanolazineCrohn's diseaseRanolazineInflammatory bowel diseaseRanolazineCandidiasisPosaconazoleAspergillus infectionPosaconazoleFungal infectionPosaconazoleOral candidiasisPosaconazoleCoccidioidomycosisPosaconazoleHistoplasmosisPosaconazoleMycobacterium tuberculosis infectionRifampicinMycobacterium leprae infectionRifampicinPulmonary tuberculosisRifampicinMeningococcal meningitisRifampicinCOVID-19RifampicinRespiratory viral infectionRifampicinHypertensionUrapidil hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Palbociclib | Tier A — Act now | 2027 |
| Olaparib | Tier A — Act now | 2028 |
| Ribociclib Succinate | Tier A — Act now | 2029 |
| Brexpiprazole | Tier A — Act now | 2029 |
| Vortioxetine Hydrobromide | Tier B — Position early | - |
| Ethambutol Hydrochloride/Rifampicin/Isoniazid | Tier C — Watch / trade | - |
| Ranolazine | Tier C — Watch / trade | - |
| Posaconazole | Tier C — Watch / trade | - |
| Rifampicin | Tier C — Watch / trade | - |
| Urapidil hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→5-bromo-2-nitropyridine→tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate→piperazine→1-(6-nitropyridin-3-yl)piperazine→PALB-044→(Z)-tert-butyl 4-(6-(2,3-bis(tert-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine-1-carboxylate→1-(5-(piperazin-1-yl)pyridin-2-yl)guanidine hydrochloride→(E)-methyl 2-acetylbut-2-enoate→6-acetyl-4-amino-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one→6-acetyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one→chlorocyclopentane→6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one→methyl 3-oxobutanoate
3-hydroxyisobenzofuran-1(3H)-one→2-fluoro-5-formylbenzonitrile→(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile→2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid→cyclopropanecarbonyl chloride→2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile→cyclopropyl(piperazin-1-yl)methanone hydrochloride→piperazine
5-bromo-2,4-dichloropyrimidine→cyclopentanamine→5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine→prop-2-yn-1-ol→3-(2-chloro-4-(cyclopentylamino)pyrimidin-5-yl)prop-2-yn-1-ol→(2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol→dimethylamine→2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide→tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate→tert-butyl 4-(6-((7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate→5-chloro-2-nitropyridine→piperazine→1-(6-nitropyridin-3-yl)piperazine→tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
7-hydroxyquinolin-2(1H)-one→1-bromo-4-chlorobutane→7-(4-chlorobutoxy)quinolin-2(1H)-one→1-(benzo[b]thiophen-4-yl)piperazine hydrochloride→4-bromobenzo[b]thiophene→piperazine
Ethambutol Hydrochloride/Rifampicin/IsoniazidOptimised routesteps: 4total yield: 572g([11C]rifampicin (FREE))
Piperazine→1-Nitrosopiperazine→1-Aminopiperazine→3-Formylrifamycin→Iodo[11C]methane→Trifluoromethanesulfonic acid [11C]methyl ester→Acetic acid (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-8-(piperazin-1-yliminomethyl)-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ester→3-(4-[11C]Methylpiperazin-1-yliminomethyl)rifamycin
((3S,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate→4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-(benzyloxy)pentan-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one→2-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one→piperazine→2-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one→1-(((2R,4R)-4-((4-bromophenoxy)methyl)-2-(2,4-difluorophenyl)tetrahydrofuran-2-yl)methyl)-1H-1,2,4-triazole→4-bromophenol
Piperazine→1-Nitrosopiperazine→1-Aminopiperazine→3-Formylrifamycin→Iodo[11C]methane→Trifluoromethanesulfonic acid [11C]methyl ester→Acetic acid (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-8-(piperazin-1-yliminomethyl)-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ester→3-(4-[11C]Methylpiperazin-1-yliminomethyl)rifamycin
6-Amino-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione→6-Chloro-1,3-dimethyluracil→3-Aminopropan-1-ol→3-Chloropropylamine hydrochloride→6-(3-Hydroxypropyl)-1,3-dimethyluracil→6-[(3-Chloropropyl)amino]-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione→1-(2-Methoxyphenyl)piperazine→1-(2-Methoxyphenyl)piperazine hydrochloride→1-(3-Aminopropyl)-4-(2-methoxyphenyl)piperazine→Pyrocatechol monomethyl ether→2-methoxyphenyl methanesulfonate→Diethylenediamine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | 2-Fluoro-5-formylbenzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 1-(Cyclopropylcarbonyl)piperazine hydrochloride Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | Tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | tert-Butyl 4-(6-((6-(1-butoxyvinyl)-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | PD 0332991 HCl Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic
acid Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6- carboxamide Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.